Concord Biotech Approves Audited Financial Results for FY 2026; Recommends Dividend
Concord Biotech Limited announced the outcomes of its Board of Directors meeting held on May 29, 2026. During the meeting, the Board approved the audited Standalone and Consolidated Financial Results for the quarter and the full financial year ended March 31, 2026. The Board also recommended a dividend for the financial year 2025-26.The company's audited results for the full financial year ending March 31, 2026, reflected a Total Comprehensive Income of 31,447.27 lakh. The Earnings Per Share (EPS) for the year reached 24.78.
The Board of Directors recommended a dividend of Rs. 7.55 per Equity Share of face value of Re. 1 each for the Financial Year 2025-26. The record date for the payment of the dividend has been set as July 24, 2026.
Financial Performance Overview (March 31, 2026 vs March 31, 2025)
The audited financial statements for the year ending March 31, 2026, presented the following operational highlights:| Particulars | Year Ended 31 March 2026 (Lakhs) | Year Ended 31 March 2025 (Lakhs) |
|---|---|---|
| Total Income | 1,10,724.60 | 1,24,453.36 |
| Total Expenses | 75,309.44 | 74,865.82 |
| Profit After Tax | 8,541.81 | 12,291.10 |
| Total Comprehensive Income | 31,447.27 | 37,761.12 |
| Total Equity | 2,01,513.80 | 1,81,271.75 |
| Total Assets | 2,23,472.71 | 2,03,425.15 |
The company’s consolidated cash flow from operating activities for the year ended March 31, 2026, stood at 26,688.13 lakh, compared to 24,451.69 lakh for the same period in 2025. The net cash used in investing activities was 14,272.36 lakh in 2026, compared to 15,998.65 lakh in 2025.
Governance and Appointments
The Board utilized the meeting to approve key corporate actions and appointments:Auditor Appointments (For FY 2026-27):
The Board approved the following appointments, based on the recommendation of the Audit Committee:
- Internal Auditor: M/s. Manubhai & Shah LLP
- Cost Auditor: M/s. Dalwadi & Associates
Directorship:
Mrs. Ekta Gupta was appointed as an Additional Independent Director, based on the recommendation of the Nomination and Remuneration Committee. Mrs. Gupta brings extensive experience across finance, hospitality, education, and manufacturing sectors.
Financial Statement Details
The consolidated statements of assets and liabilities for March 31, 2026, and March 31, 2025, are detailed below:| Particulars | As at 31 March 2026 (Lakhs) | As at 31 March 2025 (Lakhs) |
|---|---|---|
| Total Non-Current Assets | 293.66 | 89,900.93 |
| Inventories | 32,635.61 | 23,966.72 |
| Total Current Assets | 223.472 | 1,13,524.22 |
| Total Assets | 2,23,472.71 | 2,03,425.15 |
| Total Equity | 2,01,513.80 | 1,81,271.75 |
| Total Liabilities | 21,958.91 | 22,153.40 |
Key Manpower and Subsidiaries:
The audited consolidated financial results include information from wholly owned subsidiary Concord Lifegen Limited, subsidiary Stellon Biotech Inc., and joint venture Concord Biotech Japan K.K.
***
Note: All figures are presented in lakhs, unless otherwise stated.
CONCORDBIO Stock Price Movement
Concord Biotech Limited shares on Friday slipped by 4.46% to close at ₹1051.2. The equity traded on a volume of 335,959 shares during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: